drugset / Trial / NCT07032688

A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes

NCT07032688

Phase 1 Recruiting 55 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of SHR-3167 at steady state in subjects with type 2 diabetes.

Timeline

Start
2025-08-11
Primary completion
2027-03
Completion
2027-04

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-3167 Unknown
Background insulin degludec Protein / enzyme biologic